Type 2 diabetes
Conditions
Interventions
Keeping insulin degludec or insulin glargine
Switching from insulin degludec or insulin glargine to insulin degludec/insulin aspart
Sponsors
Hokkaido University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who were 20-year-old to 80-year-old at the time of obtaining informed consent 2) Patients whose HbA1c level is more than 6.0% and less than 9.0% at the time of obtaining informed consent 3) Patients who were taking insulin degludec or insulin glargine once daily more than three months and measuring their blood glucose by SMBG 4) Patients who are able to understand the study and willing to provide written informed consent
Exclusion criteria
Exclusion criteria: 1) Patients with hypersensitivity to insulin degludec/ insulin aspart 2) Patients with severe or unstable retinopathy 3) Patients with severe liver or kidney dysfunction 4) Patients with pregnancy 5) Patients with severe diabetic ketosis, diabetic coma 6) Patients who are obviously bad adherence of diet. 7) Patients who needs intensive insulin therapy due to whose insulin depletion 8) Patients who are deemed to be unsuitable by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference between pre-prandial blood glucose level and postprandial blood glucose level in main meal measured by SMBG at 12 weeks after intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Glucose variability measured by SMBG 2) Blood and urine test (including HbA1c) 3) Body weight 4) Incidence rate of hypoglycemia 5) Dose of insulin and other antidiabetic agent | — |
Countries
Japan
Contacts
Public ContactKyu Yong Cho
Hokkaido University Hospital Department of Medicine 2/Clinical Research and Medical Innovation Center
Outcome results
None listed